Submit regulatory filings for CTX001 in beta thalassemia and sickle cell disease
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Nov 2021
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Target enrollment has been achieved in the ongoing clinical trials in TDT and SCD to support the planned regulatory submissions in late 2022.”
What we found
Evidence strength A What the grades mean
Later 10-K and 8-K filings state that regulatory submissions for exa-cel in SCD and TDT to the EMA and MHRA were completed in December 2022 or the fourth quarter of 2022, before the deadline.
-
A Vertex Pharmaceuticals 8-K filed 2023-02-07
“In December 2022, Vertex completed regulatory submissions for exa-cel with the EMA and MHRA in the EU and the U.K., respectively.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In the fourth quarter of 2022, we completed regulatory submissions to the European Medicines Agency” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In the fourth quarter of 2022, we completed European regulatory submissions for exa-cel and initiated a rolling submission in the United States” ✓ confirmed on the page
Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (6 Feb 2023 to 9 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Regulatory submissions for CTX001 in TDT and SCD
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Partly met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VRTX-006506 · Corrections policy